Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Gastric & Gastroesophageal Cancer

Ken Kato

加藤健

MD, PhD

🏢National Cancer Center Hospital, Tokyo, Japan(日本国立癌症研究中心医院(东京))🌐Japan

Chief, Department of Head and Neck, Esophageal Medical Oncology头颈部及食管内科肿瘤科主任

45
h-index
2
Key Papers
3
Awards
2
Key Contributions

👥Biography 个人简介

Dr. Ken Kato is Japan's leading expert in esophageal and GEJ cancer, serving as principal investigator of CheckMate 648, which established nivolumab + chemotherapy as first-line standard for esophageal squamous cell carcinoma. He also leads HER2-targeted trials for esophageal adenocarcinoma.

Share:

🧪Research Fields 研究领域

Esophageal Cancer食管癌
Gastroesophageal Junction Cancer胃食管结合部癌
CheckMate 648CheckMate 648
Nivolumab Esophageal纳武利尤单抗食管癌
HER2-Positive Esophageal CancerHER2阳性食管癌
PD-L1 ImmunotherapyPD-L1免疫治疗

🎓Key Contributions 主要贡献

CheckMate 648: Nivolumab in Esophageal SCC

Principal investigator of CheckMate 648, demonstrating that nivolumab + chemotherapy or nivolumab + ipilimumab significantly improved OS vs. chemotherapy alone in first-line esophageal squamous cell carcinoma.

HER2-Targeted Therapy in Esophageal Cancer

Leads clinical research on HER2+ esophageal and GEJ cancer in Japan, including trastuzumab combinations and novel ADC evaluations in this subpopulation.

Representative Works 代表性著作

[1]

Nivolumab in combination with chemotherapy or ipilimumab in patients with advanced esophageal squamous cell carcinoma (CheckMate 648)

Journal of Clinical Oncology (2022)

Phase III trial establishing nivolumab-based regimens as first-line standard for advanced esophageal SCC with improved OS in PD-L1-expressing tumors.

[2]

Phase II study of trastuzumab plus chemotherapy in HER2-positive esophageal and GEJ adenocarcinoma

Gastric Cancer (2021)

Japanese phase II study demonstrating activity of trastuzumab-based therapy in HER2+ esophageal and GEJ adenocarcinoma.

🏆Awards & Recognition 奖项与荣誉

🏆Japan Society of Clinical Oncology Award for Esophageal Cancer Research
🏆National Cancer Center Japan Outstanding Investigator
🏆ESMO Annual Congress Best Abstract — Esophageal Cancer

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 加藤健 的研究动态

Follow Ken Kato's research updates

留下邮箱,当我们发布与 Ken Kato(National Cancer Center Hospital, Tokyo, Japan)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment